User profiles for Zhujun Cao
 | Zhujun CaoRuijin Hospital Verified email at rjh.com.cn Cited by 2031 |
Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial
W Tang, Z Cao, M Han, Z Wang, J Chen, W Sun, Y Wu… - bmj, 2020 - bmj.com
Objective To assess the efficacy and safety of hydroxychloroquine plus standard of care
compared with standard of care alone in adults with coronavirus disease 2019 (covid-19). …
compared with standard of care alone in adults with coronavirus disease 2019 (covid-19). …
Algorithm of Golgi protein 73 and liver stiffness accurately diagnoses significant fibrosis in chronic HBV infection
… Qing Xie, Hui Wang, Zhujun Cao and Longgen Liu coordinated the study. Zhujun Cao
was fully responsible for interpretation and statistical analysis of data. Zhujun Cao drafted the …
was fully responsible for interpretation and statistical analysis of data. Zhujun Cao drafted the …
[HTML][HTML] Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury
Acute or acute-on-chronic liver failure is a leading cause of death in liver diseases without
effective treatment. Interleukin-22 (IL-22) is currently in clinical trials for the treatment of severe …
effective treatment. Interleukin-22 (IL-22) is currently in clinical trials for the treatment of severe …
[HTML][HTML] VV116 versus nirmatrelvir–ritonavir for oral treatment of Covid-19
Z Cao, W Gao, H Bao, H Feng, S Mei… - … England Journal of …, 2023 - Mass Medical Soc
Background Nirmatrelvir–ritonavir has been authorized for emergency use by many countries
for the treatment of coronavirus disease 2019 (Covid-19). However, the supply falls short …
for the treatment of coronavirus disease 2019 (Covid-19). However, the supply falls short …
The impact of HBV flare on the outcome of HBV‐related decompensated cirrhosis patients with bacterial infection
Background Hepatitis B virus (HBV) flare can occur in HBV patients either naïve or have
interruption to treatment. Bacterial infection (BI) is a common complication of cirrhosis with …
interruption to treatment. Bacterial infection (BI) is a common complication of cirrhosis with …
The use of NACSELD and EASL-CLIF classification systems of ACLF in the prediction of prognosis in hospitalized patients with cirrhosis
Z Cao, Y Liu, M Cai, Y Xu, X Xiang… - Official journal of the …, 2020 - journals.lww.com
METHODS: This was a prospective study of nonelectively hospitalized patients with cirrhosis
(N= 468) from a single tertiary hospital between 2016 and 2018. Baseline characteristics, …
(N= 468) from a single tertiary hospital between 2016 and 2018. Baseline characteristics, …
Exacerbation of autoimmune hepatitis after COVID‐19 vaccination
Z Cao, H Gui, Z Sheng, H Xin, Q Xie - Hepatology, 2022 - journals.lww.com
… Zhujun Cao wrote the draft of the manuscript. Qing Xie and Honglian Gui revised the …
Zhujun Cao, Zike Sheng, Honglian Gui, Haiguang Xin, and Qing Xie were involved in the clinical …
Zhujun Cao, Zike Sheng, Honglian Gui, Haiguang Xin, and Qing Xie were involved in the clinical …
Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV‐related hepatocellular carcinoma
…, Y Xu, Q Zhao, S Lou, X Xiang, L Yan, Z Cao… - Cancer …, 2020 - Wiley Online Library
Background Alpha‐fetoprotein (AFP), routinely used for diagnosis of hepatocellular
carcinoma (HCC), is limited with relatively low sensitivity and high false positivity in HBV‐related …
carcinoma (HCC), is limited with relatively low sensitivity and high false positivity in HBV‐related …
[HTML][HTML] COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status
Z Cao, C Zhang, S Zhao, Z Sheng, X Xiang, R Li… - Infectious diseases of …, 2022 - Springer
Background Safety data reported from the large-scale clinical trials of the coronavirus disease
2019 (COVID-19) vaccine are extremely limited in patients with decompensated cirrhosis. …
2019 (COVID-19) vaccine are extremely limited in patients with decompensated cirrhosis. …
Global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis: a prospective cohort study for the CLEARED Consortium
Background Cirrhosis, the end result of liver injury, has high mortality globally. The effect of
country-level income on mortality from cirrhosis is unclear. We aimed to assess predictors of …
country-level income on mortality from cirrhosis is unclear. We aimed to assess predictors of …